Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS, with the Botnar Research Institute and Kennedy Institute of Rheumatology, has been designated a EULAR Centre of Excellence in Rheumatology 2015-2020, in recognition of our continued high-quality research publications in rheumatology.

EULAR, the European League Against Rheumatism, represents patients, health professionals and scientific societies of rheumatology of all European nations. It aims to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases.

Its Centres of Excellence are top rheumatology research units in Europe aiming to develop a group of first-class research centres for active researchers and enable exchange of fellows and research projects.

NDORMS is one of the largest and most dynamic multidisciplinary academic rheumatology research centres in the world, with over 50 dedicated researchers focusing on rheumatic conditions.

We have one of the largest and broadest groupings of translational rheumatology research in the world; covering inflammatory, degenerative and congenital diseases of the musculoskeletal system. Scientific approaches include direct patient-focused research, epidemiology, and basic mechanistic research in immunology, genetics, bone, matrix and cartilage biology.

Professor Paul Bowness, who led on the department's application, assisted by Professor Richard Williams from the Kennedy Institute said: "We are delighted with this award and the recognition it brings to NDORMS for its research into diverse rheumatic conditions and important rheumatology research is for the lives of millions of people around the world. This supports our mission to develop and deliver excellent clinical and basic research and foster collaborations with other Centres of Excellence."

Similar stories

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.

Building a humanoid bioreactor

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.